Abstract：Objective To study the clinical efficacy of modified PCH regimen (Trastuzumab+Paclitaxel+Carboplatin) for locally advanced female breast cancer with positive human epidermal growth factor receptor 2 (HER-2). Methods A total of 134 patients with locally advanced female breast cancer with positive HER-2 admitted to Binhai People’s Hospital Affiliated to Kangda College of Nanjing Medical University were selected, they were divided into observation group and control group by random number table method, with 67 cases in each group. The control group received Paclitaxel and Carboplatin, and the observation group received modified PCH regimen. After chemotherapy, both groups received modified radical mastectomy for breast cancer. The clinical efficacy of two groups was observed; serum tissue polypeptide specific antigen (TPS) and carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), CD3+, CD4+, CD8+, and CD4+/CD8+ were detected before treatment and six months after treatment; the incidence of adverse reactions in two groups was recorded. Results The disease control rate in observation group was higher than that in control group (P ＜ 0.05). Six months after treatment, the levels of TPS, CEA, and CA125 in both groups were lower than those before treatment, and observation group was lower than control group (P < 0.05). Six months after treatment, CD3+, CD4+, and CD4+/CD8+ in both groups were decreased compared with before treatment (P < 0.05); there was no significant difference in CD8+ levels between two groups (P > 0.05). Six months after treatment, there were no significant differences in CD3+, CD4+, CD8+, and CD4+/CD8+ between two groups (P > 0.05). The total incidence of adverse reactions in observation group was lower than that in control group (P < 0.05). Conclusion Modified PCH regimen has a good efficacy for locally advanced female breast cancer with positive HER-2, which can reduce serum tumor marker level and is not likely to damage immune function, with high safety.
京公网安备 11010502046598号